Journal ArticleDOI
Natural Products as Sources of New Drugs over the Period 1981−2002
Reads0
Chats0
TLDR
From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.Abstract:
This review is an updated and expanded version of a paper that was published in this journal in 1997. The time frame has been extended in both directions to include the 22 years from 1981 to 2002, and a new secondary subdivision related to the natural product source but applied to formally synthetic compounds has been introduced, using the concept of a “natural product mimic” or “NM” to join the original primary divisions. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame. In other areas, the influence of natural product structures is quite marked, particularly in the antihypertensive area, where of the 74 formally synthetic drugs, 48 can be traced to natural product structures/mimics. Similarly, with the 10 antimigraine drugs, seven are bas...read more
Citations
More filters
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003 and is able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame.
Journal ArticleDOI
Marine natural products.
TL;DR: This review covers the literature published in 2014 for marine natural products, with 1116 citations referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and other intertidal plants and microorganisms.
Journal ArticleDOI
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012, and the time frame has been extended to cover the 34 years from January 1, 1981, to December 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2014 for all approved antitumor drugs worldwide.
Journal ArticleDOI
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of the three prior reviews and adds a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations.
Journal ArticleDOI
The growing impact of click chemistry on drug discovery.
TL;DR: The copper-(I)-catalyzed 1,2,3-triazole formation from azides and terminal acetylenes is a particularly powerful linking reaction, due to its high degree of dependability, complete specificity, and the bio-compatibility of the reactants.
References
More filters
Journal ArticleDOI
The influence of natural products upon drug discovery.
Journal ArticleDOI
Natural products in cancer chemotherapy: past, present and future
TL;DR: The quickening pace of (aberrant) gene identification, and the new technologies of combinatorial chemistry and high-throughput screening, should provide access to a wide range of new, totally synthetic drugs.
Journal ArticleDOI
Angiotensin Receptors and Their Antagonists
TL;DR: The intrarenal renin–angiotensin system affects glomerular filtration, as discussed below, but the importance of ang Elliotensin synthesis in other tissues is not known.
Journal ArticleDOI
Comparative genome and proteome analysis of Anopheles gambiae and Drosophila melanogaster.
Evgeny M. Zdobnov,Christian von Mering,Ivica Letunic,David Torrents,Mikita Suyama,Richard R. Copley,George K. Christophides,Dana Thomasova,Robert A. Holt,G. Mani Subramanian,Hans Michael Mueller,George Dimopoulos,John H. Law,Michael A. Wells,Ewan Birney,Rosane Charlab,Aaron L. Halpern,Kokoza Eb,Cheryl L. Kraft,Zhongwu Lai,Suzanna E. Lewis,Christos Louis,Carolina Barillas-Mury,Deborah Nusskern,Gerald M. Rubin,Steven L. Salzberg,Granger G. Sutton,Pantelis Topalis,Ron Wides,Patrick Wincker,Mark Yandell,Frank H. Collins,José M. C. Ribeiro,William M. Gelbart,Fotis C. Kafatos,Peer Bork +35 more
TL;DR: Aligned sequences reveal that orthologous genes have retained only half of their intron/exon structure, indicating that intron gains or losses have occurred at a rate of about one per gene per 125 million years, which indicates that these two insects diverged considerably faster than vertebrates.
Journal ArticleDOI
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
David J. Carini,J V Duncia,Paul E. Aldrich,Andrew T. Chiu,Alexander L. Johnson,Michael E. Pierce,William A. Price,J B Santella rd,Gregory J. Wells,Ruth R. Wexler +9 more
TL;DR: A new series of nonpeptide angiotensin II (AII) receptor antagonists has been prepared, and it has been found that the acidic group at the 2'-position of the biphenyl is essential.
Related Papers (5)
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more